Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants

Tan, K.; Li, Ruizhen; Huang, Xiaotian; Liu, Qiong

doi:10.3389/fmicb.2018.00783

Cited by 143 publications

(123 citation statements)

References 99 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…This vaccine formulation was adopted in study 1 in order to compare the response elicited by immunizing solely with FlfA + GtxA-N against the response elicited when G. anatis OMVs were also added to the vaccine formulation. Given that immunization with both FlfA [18,22] and GtxA-N [23] was previously reported to be effective in providing protection when co-administered with G. anatis OMVs or other adjuvants, and considering the well known adjuvant role exerted by the OMVs [17,20], the lack of protection observed in group 2 can most likely be attributed to the absence of an adjuvant in the vaccine formulation FlfA + GtxA-N.…”

Section: Discussionmentioning

confidence: 99%

“…This observation may be explained considering once more the adjuvant properties of the OMVs and the host immune response to the vesicles. The OMVs exhibit on their surface a variety of pathogen-associated molecular patterns (PAMPs) [13], molecules able to elicit an immune response in the host ultimately by recruiting and activating antigen-presenting cells (APCs) [20]. This process is partly mediated by the release of pro-inflammatory cytokines by host immune effectors, the concentration of which can affect the balance between an inflammatory and adaptive response [41].…”

Section: Discussionmentioning

confidence: 99%

“…Moderate levels of inflammation can potentiate the response to an administered immunogen, and for this reason pro-inflammatory compounds such as adjuvants are generally included in vaccine formulations. High levels of inflammation, such as the ones generated by the administration of high concentrations of PAMPs, are on the other hand generally disruptive for the achievement of an effective adaptive immune response [20,40]. An example of the effect of high concentrations of PAMPs on the immune system has been reported in mice, where the administration of high concentrations of LPS was shown to disrupt the B cells response to T-dependent antigens [42].…”

Section: Discussionmentioning

confidence: 99%

“…This feature leaves OMVs as ideal candidates for the development of novel vaccines against Gram-negative pathogens [15], a fact that has been proven by the development and commercialization of an effective OMV-based vaccine against Neisseria meningitidis for human use [16]. Additionally, the OMVs have been shown to act as a potent adjuvant when co-administered with other immunogens [17][18][19], further increasing the possible applications of vesicles in vaccine development [20]. Our group previously reported that G. anatis secretes OMVs [21], and that these vesicles, in combination with the conserved proteins FlfA or the N-terminal of the GtxA toxin [22][23][24], are effective in preventing the development of lesions associated with G. anatis infections when administered as immunogens [18,25].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hydrostatic Filtration Enables Large-Scale Production of Outer Membrane Vesicles That Effectively Protect Chickens against Gallibacterium anatis

et al. 2020

View full text Add to dashboard Cite

Gallibacterium anatis is a Gram-negative opportunistic avian pathogen representing an emerging threat to poultry meat and egg production worldwide. To date, no vaccine able to effectively prevent the morbidity associated with G. anatis infections has been developed yet. Our group previously reported that inoculation of different combinations of G. anatis outer membrane vesicles (OMVs), FlfA and GtxA-N proteins is effective in preventing lesions caused by G. anatis infections in layer chickens. Here we report the testing of the efficacy as vaccine prototypes of G. anatis OMVs isolated by hydrostatic filtration, a simple technique that allows the cost-effective isolation of high yields of OMVs. Layer chickens were immunized with OMVs alone or in combination with FlfA and/or GtxA-N proteins. Subsequent challenge with a heterologous G. anatis strain showed that immunization with OMVs alone could significantly reduce the lesions following a G. anatis infection. A second study was carried out to characterize the dose-response (0.25, 2.5 and 25 µg) relationship of G. anatis OMVs as immunogens, showing that 2.5 μg of OMVs represent the optimal dose to elicit protection in the immunized animals after a similar challenge. Additionally, administration of ≥2.5 μg of G. anatis OMVs induced specific IgY titers and possibly vertical transfer of immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hydrostatic Filtration Enables Large-Scale Production of Outer Membrane Vesicles That Effectively Protect Chickens against Gallibacterium anatis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The multiantigenic nature of OMVs makes them attractive candidates for antibacterial vaccination. Their unique membrane protein profile activates both the innate and adaptive immune systems, and these responses are prompted by the presentation of PAMPs that bind to PRRs on APCs . In addition, their small size increases their lymph node entry and APC uptake rates, further improving their immune activation capabilities.…”

Section: Biomimetic Antibacterial Nanovaccinesmentioning

confidence: 99%

Biomimetic Nanotechnology toward Personalized Vaccines

et al. 2019

View full text Add to dashboard Cite

While traditional approaches for disease management in the era of modern medicine have saved countless lives and enhanced patient well‐being, it is clear that there is significant room to improve upon the current status quo. For infectious diseases, the steady rise of antibiotic resistance has resulted in super pathogens that do not respond to most approved drugs. In the field of cancer treatment, the idea of a cure‐all silver bullet has long been abandoned. As a result of the challenges facing current treatment and prevention paradigms in the clinic, there is an increasing push for personalized therapeutics, where plans for medical care are established on a patient‐by‐patient basis. Along these lines, vaccines, both against bacteria and tumors, are a clinical modality that could benefit significantly from personalization. Effective vaccination strategies could help to address many challenging disease conditions, but current vaccines are limited by factors such as a lack of potency and antigenic breadth. Recently, researchers have turned toward the use of biomimetic nanotechnology as a means of addressing these hurdles. Recent progress in the development of biomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis on their potential for personalized medicine.

show abstract